Standard BioTools Inc.
LABNASDAQHealthcare● Active
$0.84
$-0.31(-27.18%)
Market Cap$326894264
P/E Ratio—
52W High$1.72
52W Low$0.8081
Standard BioTools Inc. (LAB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LAB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.02
Est. -$0.02 · +0.0%
Revenue
$0.02B
Est. $0.02B · +18.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
LAB reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.01 | — | — | — | $0.02B | — |
| — Q2 FY2026 | May 5, 2026 | -$0.02 | -$0.02 | +0.0% | $0.02B | $0.02B | +18.8% |
| ▲ Q1 FY2026 | Feb 24, 2026 | -$0.03 | $0.06 | +300.0% | $0.02B | $0.02B | +28.6% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.03 | -$0.04 | -60.0% | $0.02B | $0.02B | +5.7% |
| — Q3 FY2025 | Aug 11, 2025 | -$0.04 | -$0.04 | +0.0% | $0.02B | $0.04B | -46.8% |
| — Q2 FY2025 | May 6, 2025 | -$0.04 | -$0.04 | +0.0% | $0.04B | $0.04B | +4.0% |
| ▲ Q1 FY2025 | Feb 26, 2025 | -$0.07 | -$0.05 | +28.6% | $0.05B | $0.04B | +8.6% |
| ▲ Q4 FY2024 | Oct 30, 2024 | -$0.08 | -$0.05 | +37.5% | $0.04B | $0.04B | +4.5% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
+0.0%
Revenue
$0.02B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
$0.06
EPS Est.
-$0.03
EPS Surpr.
+300.0%
Revenue
$0.02B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.04
EPS Est.
-$0.03
EPS Surpr.
-60.0%
Revenue
$0.02B
Q3 FY2025
Aug 11, 2025
EPS Actual
-$0.04
EPS Est.
-$0.04
EPS Surpr.
+0.0%
Revenue
$0.02B
Q2 FY2025
May 6, 2025
EPS Actual
-$0.04
EPS Est.
-$0.04
EPS Surpr.
+0.0%
Revenue
$0.04B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.07
EPS Surpr.
+28.6%
Revenue
$0.05B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
-$0.05
EPS Est.
-$0.08
EPS Surpr.
+37.5%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2028 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q2 FY2028 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q1 FY2028 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q4 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +0.0% | $0.94 | $0.98 | +4.71% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +300.0% | $1.11 | $1.15 | +3.60% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -60.0% | $1.24 | $1.19 | -4.03% |
| ▲ Q3 FY2025 | Aug 11, 2025 | +0.0% | $1.31 | $1.28 | -2.29% |
| ▲ Q2 FY2025 | May 6, 2025 | +0.0% | $1.15 | $1.06 | -7.83% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +28.6% | $1.26 | $1.17 | -7.14% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +37.5% | $1.75 | $1.88 | +7.43% |
| ▼ Q3 FY2024 | Jul 31, 2024 | -33.3% | $2.32 | $2.24 | -3.45% |
Q2 FY2026+4.71%
Report Date
May 5, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.94
Price After
$0.98
Q1 FY2026+3.60%
Report Date
Feb 24, 2026
EPS Beat/Miss
+300.0%
Price Before
$1.11
Price After
$1.15
Q4 FY2025-4.03%
Report Date
Nov 4, 2025
EPS Beat/Miss
-60.0%
Price Before
$1.24
Price After
$1.19
Q3 FY2025-2.29%
Report Date
Aug 11, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.31
Price After
$1.28
Q2 FY2025-7.83%
Report Date
May 6, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.15
Price After
$1.06
Q1 FY2025-7.14%
Report Date
Feb 26, 2025
EPS Beat/Miss
+28.6%
Price Before
$1.26
Price After
$1.17
Q4 FY2024+7.43%
Report Date
Oct 30, 2024
EPS Beat/Miss
+37.5%
Price Before
$1.75
Price After
$1.88
Q3 FY2024-3.45%
Report Date
Jul 31, 2024
EPS Beat/Miss
-33.3%
Price Before
$2.32
Price After
$2.24
Avg Beat Reaction-0.25%
Avg Miss Reaction-3.74%
Beat Rate6 / 8 quarters
Largest Move-7.83% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LAB ends December
Standard BioTools Inc. (LAB) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.02 (in line with the analyst consensus of $-0.02). LAB has beaten EPS estimates for 2 consecutive quarters. The next LAB earnings date is expected around September 1, 2026.
Each quarter, investors track LAB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LAB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LAB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LAB earnings · 4 questionsStandard BioTools Inc.'s next earnings report is expected around September 1, 2026. LAB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LAB historically reports after market close (AMC).
LAB earnings datewhen is LAB earningsLAB next earnings datewhen does LAB report earningsLAB earnings calendar
▸ Source: FMP · Standard BioTools Inc. SEC filings · US GAAP · Standard BioTools Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026